Helicos BioSciences (HLCS) carries out successful landmark study of molecule

Helicos BioSciences (NYSE: HLCS)  announced the publication of a landmark study in which HLCS's True Single Molecule Sequencing technology was used to directly sequence individual molecules of RNA. The paper appeared yesterday in the on-line edition of Nature and will appear in an upcoming 2009 print issue of Nature. HLCS stock moved up by 12.75% in early trade to $2.75 on high volumes, thus showing signs of bullish trend.